New Two-Step transplant shows promise for tough blood cancers
NCT ID NCT01315132
First seen Mar 21, 2026 · Last updated May 02, 2026 · Updated 7 times
Summary
This study tested a two-step stem cell transplant using a drug called cyclophosphamide to lower the risk of graft-versus-host disease (GVHD) in people with high-risk blood cancers like leukemia and lymphoma. 47 patients received a transplant from a matched sibling donor. The goal was to see if more than 60% of patients would survive at least one year after the transplant. The approach aims to improve survival by making the transplant safer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.